Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)
ID: 355430Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355430

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-049.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)" through the National Institute of Allergy and Infectious Diseases (NIAID). This initiative aims to identify critical factors driving TB transmission in high-burden areas and to develop effective measurement and intervention strategies, including low-cost methods to prevent and detect infectious TB. With a total funding amount of $6 million available for 4-5 awards in FY 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Applications are due by December 5, 2024, and interested parties can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-049-Full-Announcement.html
    RFA-AI-24-049.html
    The National Institutes of Health (NIH) is announcing a funding opportunity through the National Institute of Allergy and Infectious Diseases (NIAID) titled "Halting Tuberculosis (TB) Transmission" (R01 Clinical Trial Optional). The goal is to identify key factors driving TB transmission in high-burden areas and develop effective measurement and intervention strategies, including low-cost methods to prevent and detect infectious TB. A total of $6 million is available for 4-5 awards in FY 2025, with applications due by December 5, 2024. Eligible applicants include a wide range of organizations, from higher education institutions to nonprofits and foreign entities. Applications should address specific research objectives, such as understanding the role of asymptomatic TB in transmission, and must comply with stringent application instructions. Investigators are encouraged to leverage advancements in technology for data collection and tracking of TB transmission. The review process will evaluate scientific and technical merit, considering factors like significance, innovation, approach, and the qualifications of the research team. This funding aims to support critical research that can significantly impact global health efforts against tuberculosis, one of the leading infectious disease killers worldwide.
    Similar Opportunities
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection," aimed at supporting research into the mechanisms of host cell death related to Mycobacterium tuberculosis (Mtb) and HIV co-infections. The initiative seeks to identify immune targets for the development of host-directed therapies by studying both inflammatory and non-inflammatory cell death pathways, emphasizing the need for multidisciplinary research teams that may include experts in HIV, TB, cell biology, and oncology. This grant does not have a funding cap, but proposals must align with project needs, and the maximum project period is five years. Interested applicants, including various educational and nonprofit institutions, must submit their applications by December 7, 2024, through Grants.gov, adhering to the NIH Grants Policy Statement. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Promoting Innovative Research in Treponema pallidum Pathogenesis" (R21 Clinical Trial Not Allowed), aimed at supporting exploratory research to enhance understanding of the pathogenesis of Treponema pallidum, the bacterium responsible for syphilis. This initiative is particularly relevant given the rising rates of sexually transmitted infections (STIs) and the increase in congenital syphilis cases, emphasizing the need for innovative research techniques to lower barriers in this field. The total funding commitment for Fiscal Year 2025 is $2 million, with plans to award 4 to 6 grants, allowing applicants to request budgets up to $275,000 for projects lasting no more than two years. Interested applicants should submit their proposals by November 4, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Approaches for TB Prevention and Case Finding to END TB
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is forecasting a federal grant opportunity titled "Innovative Approaches for TB Prevention and Case Finding to END TB." This initiative aims to develop, implement, and evaluate innovative strategies for tuberculosis (TB) prevention and case finding, focusing on high-burden settings and vulnerable populations, including those living with HIV, children, and economically disadvantaged individuals. The total estimated program funding is $5 million, with an award ceiling of $1 million for up to two cooperative agreements, and applications are expected to be submitted electronically by February 27, 2025. Interested applicants can reach out to Hoang Dang at 404.639.8965 or via email at hdang@cdc.gov for further information.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Tobacco Regulatory Science (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Tobacco Regulatory Science (R01 Clinical Trial Optional)" funding opportunity, aimed at supporting biomedical and behavioral research to inform the regulation of tobacco products and protect public health. This initiative seeks R01 research project grant applications that address key research priorities, including the composition and design of tobacco products, toxicity assessments, addiction studies, and the health effects of tobacco use. A total of up to six R01 grants, with a combined funding of $4 million for fiscal year 2024, will be awarded to eligible applicants, which include a diverse range of institutions and organizations. Interested parties should submit their applications by May 4, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html for further details.